EICHORCondition: Myelofibrosis · Leukemia, Myelocytic, Acute · Myelodysplastic/Myeloproliferative Neoplasm · Sponsor: Constellation Pharmaceuticals
Phase 1 Part: This was an open-label, sequential dose escalation study of pelabresib (CPI-0610) in patients who had previously been treated for Acute Leukemia, Myelodysplastic/Myeloproliferative Neoplasms. Phase 2 Part: This was an open-label study of pelabresib (CPI-0610), administered with and without Ruxolitinib, in patients diagnosed with Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia). Pelabresib (CPI-0610) was a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Mayo Clinic Arizona | Phoenix, Arizona, United States | — |
| UCLA Medical Center | Los Angeles, California, United States | — |
| Mayo Clinic Jacksonville | Jacksonville, Florida, United States | — |
| Northwestern University - Lurie Comprehensive Cancer Center | Chicago, Illinois, United States | — |
| Massachusetts General Hospital Cancer Center | Boston, Massachusetts, United States | — |
| University of Michigan Medical Center | Ann Arbor, Michigan, United States | — |
| Washington University School of Medicne Neuromuscular Division Department of Neurology Research | St Louis, Missouri, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| ICAHN School of Medicine at Mount Sinai | New York, New York, United States | — |
| Weill Medical College and New York Presbyterian Hospital | New York, New York, United States | — |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | — |
| Froedtert & Medical College of Wisconsin | Milwaukee, Wisconsin, United States | — |
+ 36 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02158858